PNC-27
ExperimentalExperimental anticancer peptide / researchExperimental
Experimental peptide containing a p53 motif designed to lyse cancer-cell membranes in preclinical papers. Not FDA-approved; not a cancer treatment.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- —
- Unit
- mg
- Administration Route
- Research only
- Frequency
- —
- Last updated
- Aug 23, 2026
- Targets
- Membrane HDM-2 (claimed)
Overview
Experimental peptide containing a p53 motif designed to lyse cancer-cell membranes in preclinical papers. Not FDA-approved; not a cancer treatment.
Protocol
- Dosage Range
- Not established — preclinical only
- Frequency
- —
- Cycle
- —
- Administration Route
- Research only
- Reconstitution Guide
- —
- Injection Sites
- AbdomenThigh
- Timing Notes
- Educational catalog only — not medical advice
Science
Mechanism of Action
Reported to bind HDM-2 in cancer-cell membranes and induce transmembrane pores. Evidence is preclinical; unregulated products are not oncology drugs.
Origin
Synthetic p53-derived peptide.
Targets
Membrane HDM-2 (claimed)
Studies
Benefits
Oncology-mechanism research tool
Potential Side Effects
Side Effects
- Unknown; membrane-lytic peptides can be cytotoxic
References
- PMID 21956412External reference